Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates

Transfusion

Volumn 49, Issue 12, 2009, Pages 2631-2636

  Ambruso, Daniel R ^a,b,c   Thurman, Gail ^a,b,c   Marschner, Susanne ^a,b,c   Goodrich, Raymond P ^a,b,c  

^a Bonfils Blood Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CaridianBCT Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; RIBOFLAVIN; THROMBOCYTE ANTIGEN; THROMBOCYTE CONCENTRATE; VERY LATE ACTIVATION ANTIGEN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBODY PRODUCTION; APHERESIS; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION;

ANTIGENS, HUMAN PLATELET; AUTOANTIBODIES; BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; ISOANTIBODIES; PHOTOSENSITIZING AGENTS; PLATELET TRANSFUSION; PLATELETPHERESIS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 71849096973     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02347.x     Document Type: Article

References (17)

1. Klein HG, Anderson D, Bernardi M, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007 47 : 2338 47. (Pubitemid 350151213)
2. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007 47 : 2180 4.
3. Speck WT, Chen CC, Rosenkranz HS. In vitro studies of effects of light and riboflavin on DNA and HeLa cells. Pediatr Res 1975 9 : 150 3.
4. Ruane P, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
5. ® PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
6. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005 45 : 1335 41.
7. Li J, Goodrich L, Hansen E, Edrich R, Gampp D, Goodrich RP. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005 45 : 1750 8.
8. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P. Correlation of in vitro platelet quality measurements with in vitro platelet viability in human subjects. Vox Sang 2006 90 : 279 85.
9. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004 87 : 82 90.
10. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005 45 : 920 6.
11. Goodrich R, Folléa G, Roberts T. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008 48s : 20A.
12. Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
13. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-γc-/- double knockout mice. Transfusion 2006 46 : 1553 60.
14. Unna K, Greslin JG. Studies on the toxicity and the pharmacology of riboflavin. J Pharmacol 1942 76 : 75 80.
15. Sisson TR. Photodegradation of riboflavin in neonates. Fed Proc 1987 46 : 1883 5.
16. Kale H, Harikumar P, Nair PM, Netrawali MS. Assessment of the genotoxic potential of riboflavin and lumiflavin. A. Effect of metabolic enzymes. Mutat Res 1992 298 : 9 16.
17. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008 22 : 133 53.